title: Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test.
authors.forename: James H
authors.initials: JH
authors.lastname: Willig
authors.forename: Christa R
authors.initials: CR
authors.lastname: Nevin
authors.forename: James L
authors.initials: JL
authors.lastname: Raper
authors.forename: Michael S
authors.initials: MS
authors.lastname: Saag
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Mugavero
authors.forename: Amanda L
authors.initials: AL
authors.lastname: Willig
authors.forename: Jeffrey H
authors.initials: JH
authors.lastname: Burkhardt
authors.forename: Joseph E
authors.initials: JE
authors.lastname: Schumacher
authors.forename: Victoria A
authors.initials: VA
authors.lastname: Johnson
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000097:blood* / Q000188:drug therapy / Q000191:economics*; D019380:Anti-HIV Agents / Q000627:therapeutic use; D044966:Anti-Retroviral Agents / Q000191:economics / Q000627:therapeutic use; D017281:Cost of Illness; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D012367:RNA, Viral / Q000097:blood*; D019562:Viral Load / Q000379:methods*; D014766:Viremia / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy
chemical_list: D019380:Anti-HIV Agents; D044966:Anti-Retroviral Agents; D012367:RNA, Viral